MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
426.71%
Quick Ratio
371.60%
Cash Ratio
179.73%
Debt to Asset Ratio
63.16%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Accounts receivable, net
    • Deferred tax assets
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Loan payable non-current
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
482,575
442,209
79,148
74,081
Short-term investment securities
69,673
72,221
62,822
57,501
Accounts receivable, net
401,565
392,046
305,628
265,384
Inventory
147,973
129,029
125,586
146,953
Other current assets
43,901
51,464
57,580
55,846
Total current assets
1,145,687
1,086,969
630,764
599,765
Restricted cash
1,364
1,352
1,342
1,329
Long-term investment securities
64,368
61,538
59,136
48,757
Right of use assets
7,085
6,481
6,278
6,501
Deferred tax assets
343,428
344,136
348,000
366,627
Non-current inventories
75,486
26,346
15,689
-
Other noncurrent assets
2,211
2,015
2,044
2,045
Total assets
1,639,629
1,528,837
1,063,253
1,025,024
Accounts payable and accrued expenses
213,693
148,845
107,508
112,336
Other current liabilities
857
596
2,124
1,993
Lease liability current portion
1,913
1,822
1,044
1,068
Deferred revenue - current portion
16,825
17,190
21,234
26,399
Accrued compensation
35,205
18,655
21,850
15,014
Total current liabilities
268,493
187,108
153,760
156,810
Deferred revenue, non-current portion
14,525
6,863
8,807
8,348
Loan payable non-current
745,387
745,140
245,645
245,340
Lease liability non-current
7,141
6,595
7,021
7,308
Total liabilities
1,035,546
945,706
415,233
417,806
Common stock, 0.001 par value per share (190,000,000 and 190,000,000 shares authorized, 159,949,330 and 158,849,596 shares issued, 153,077,784 and 155,305,953 shares outstanding at june 30, 2026 and december 31, 2025, respectively)
160
160
159
159
Additional paid-in capital
1,858,606
1,845,435
1,830,110
1,812,345
Treasury stock, at cost, 3,543,643 and 367,903 shares at december 31, 2025 and december 31, 2024
-
-
100,234
100,234
Treasury stock, at cost, 6,871,546 and 3,543,643 shares at june 30, 2026 and december 31, 2025, respectively
200,226
200,226
-
-
Accumulated deficit
-1,054,457
-1,062,238
-1,082,015
-1,105,052
Total stockholders equity
604,083
583,131
648,020
607,218
Total liabilities and stockholders equity
1,639,629
1,528,837
1,063,253
1,025,024
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$482,575K (273.72%↑ Y/Y)Accounts receivable, net$401,565K (73.45%↑ Y/Y)Inventory$147,973K (-4.66%↓ Y/Y)Short-term investmentsecurities$69,673K (-43.24%↓ Y/Y)Other current assets$43,901K (73.02%↑ Y/Y)Total current assets$1,145,687K (72.55%↑ Y/Y)Deferred tax assets$343,428K Non-current inventories$75,486K Long-term investmentsecurities$64,368K (125.14%↑ Y/Y)Right of use assets$7,085K (5.46%↑ Y/Y)Other noncurrentassets$2,211K (9.08%↑ Y/Y)Restricted cash$1,364K (3.65%↑ Y/Y)Total assets$1,639,629K (133.36%↑ Y/Y)Total liabilities andstockholders equity$1,639,629K (133.36%↑ Y/Y)Total liabilities$1,035,546K (142.98%↑ Y/Y)Total stockholdersequity$604,083K (118.53%↑ Y/Y)Accumulated deficit-$1,054,457K (29.51%↑ Y/Y)Treasury stock, at cost,6,871,546 and 3,543,643...$200,226K (810.45%↑ Y/Y)Loan payable non-current$745,387K (204.19%↑ Y/Y)Total currentliabilities$268,493K (56.20%↑ Y/Y)Deferred revenue,non-current portion$14,525K (771.33%↑ Y/Y)Lease liability non-current$7,141K (-5.89%↓ Y/Y)Additional paid-in capital$1,858,606K (3.59%↑ Y/Y)Common stock, 0.001 parvalue per share...$160K (0.63%↑ Y/Y)Accounts payable andaccrued expenses$213,693K (59.45%↑ Y/Y)Accrued compensation$35,205K (231.81%↑ Y/Y)Deferred revenue -current portion$16,825K (-29.63%↓ Y/Y)Lease liability current portion$1,913K (75.34%↑ Y/Y)Other currentliabilities$857K (-62.01%↓ Y/Y)
TG Therapeutics BRIUMVI Approval Call Slide Deck 12

TG THERAPEUTICS, INC. (TGTX)

TG Therapeutics BRIUMVI Approval Call Slide Deck 12

TG THERAPEUTICS, INC. (TGTX)